$279.00
+1.6%BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Chief Financial Officer
Compensation
$1,928,439
Chief Technology Officer
Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
Compensation
$4,249,950
Co-Founder, Executive Chairman & Chief Executive Officer
Compensation
$2,836,747
General Counsel & Senior Vice President
Compensation
$1,076,400
Global Head of Research & Development
Compensation
$1,202,653
Head of Investor Relations
President, Chief Operating Officer & GM of China
Compensation
$1,838,195
Senior VP & Head of Corporate Communications
Vice President & Chief Accounting Officer
During the last 12 months, insiders have sold $1.56M worth of ONC shares, with no buying activity reported.
0
0.00
4.4K
571.21K
-571K
-$571K
0
0.00
3.1K
992.01K
-992K
-$992K
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
No buying activity
Lee Chan Henry
Officer: Svp, General Counsel
$761K
Oyler John
Director, Officer: Chief Executive Officer
$540K
Dugan Margaret
Director
$66K
Sanders Corazon (Corsee) D.
Director
$66K
Riva Alessandro
Director
$66K
Strong bearish signal with $1.56M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
ONC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 07, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 09, 2020 | November 20, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 17, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | November 29, 2019 | December 27, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 05, 2019 | 2019 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.